摘要
背景:乳腺癌是女性癌症的主要形式,它也依赖于激素。根据受体的表达,这些癌症被细分为不同的形式,在这些受体中,雌激素、孕酮和Her2是重要的。靶向乳腺癌(BC)因其性质不同,一直很困难;然而,各种植物化合物,特别是那些具有雌激素样特性的,已被证明是有效的。 目的:本文综述抑制乳腺癌增殖进展的各种植物化合物,重点介绍植物雌激素的作用及其分子作用机制。 方法:数据来自PubMed/Medline、科学网络、科学直接、生态系统选择等知名数据库。以个体名和“植物雌激素”为关键词,收集植物雌激素的数据。发表在汤森路透(SCI/SCIE/ESCI)索引的文章被省略。 结果:天然产物是治疗多种形式乳腺癌的重要候选药物。除了起始和增殖事件外,这些分子还抑制上皮细胞向间充质细胞的转化(EMT)和BC的转移。植物雌激素是一类重要的已知雌激素潜能的化合物;研究也表明,这些分子在BC的细胞培养和动物模型中具有抗癌潜力。 结论:天然植物化合物,特别是植物雌激素,是一种很有前途的抗乳腺癌药物,可诱导细胞周期阻滞、凋亡和自噬介导的细胞死亡。然而,需要更多的临床研究,以便这些分子可以作为商业药物分子使用。
关键词: 乳腺癌,植物雌激素,天然产物,转移,细胞凋亡,耐药性。
图形摘要
Current Drug Targets
Title:Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens
Volume: 22 Issue: 11
关键词: 乳腺癌,植物雌激素,天然产物,转移,细胞凋亡,耐药性。
摘要:
Background: Breast cancer is the leading form of cancer in women, which is also hormone- dependent. Depending on the receptor expression, these cancers are subdivided into different forms, and among these receptors, estrogen, progesterone, and Her2 are the important ones. Targeting breast cancer (BC) has been difficult due to their varied nature; however, various phytocompounds, especially those having estrogen-like properties, have proven to be effective.
Objective: The present review is aimed to provide a detailed description of various Phytocompounds inhibiting breast cancer proliferation and progression; emphasis has been given to the role of phytoestrogens with their molecular mechanism of action.
Methods: The data were collected from reputed databases, such as PubMed/Medline, Web of Science, Science Direct, Eurekaselect, etc. Data on the phytoestrogens were collected using individual names and “phytoestrogens” as keywords. Articles published in journals, which are not indexed by Thomson Reuters (SCI/SCIE/ESCI), were omitted.
Results: Natural products are important drug candidates against multiple forms of breast cancer. In addition to the initiation and proliferation events, these molecules inhibit epithelial to mesenchymal transition (EMT) and metastasis of BC. Phytoestrogens are an important class of compounds which have known estrogenic potential; studies have also indicated the anticancer potentials of these molecules in cell culture and animal models of BC.
Conclusion: Natural plant compounds, especially phytoestrogens, are promising anti-breast cancer agents that induce cell cycle arrest, apoptosis, and autophagy-mediated cell death. However, more clinical studies are necessary so that these molecules can be used as commercial drug molecules.
Export Options
About this article
Cite this article as:
Natural Bioactive Compounds as Emerging Therapeutic Molecules Against Breast Cancer: Emphasis on the Role of Phytoestrogens, Current Drug Targets 2021; 22 (11) . https://dx.doi.org/10.2174/1389450121999201109215341
DOI https://dx.doi.org/10.2174/1389450121999201109215341 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Status of Primary Cytoreductive Surgery for the Treatment of Advanced Epithelial Ovarian Cancer
Current Cancer Therapy Reviews Metabolomics for Personalized Nutrition Research and Clinical Applications
Current Pharmacogenomics and Personalized Medicine Meet the Editorial Board:
Anti-Cancer Agents in Medicinal Chemistry Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Synthesis, Cytotoxic Evaluation, and Molecular Docking Studies of N-(7- hydroxy-4-methyl-2-oxoquinolin-1(2H)-yl)acetamide/benzamide Analogues
Letters in Drug Design & Discovery Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Functional Properties of Kefiran in the Medical Field and Food Industry
Current Pharmaceutical Biotechnology Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Editorial [Hot Topic:Toward Translational Research on VIP AND PACAP (Executive Editor: A. Arimura)]
Current Pharmaceutical Design PROTACs: A Hope for Breast Cancer Patients?
Anti-Cancer Agents in Medicinal Chemistry Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Multiple Functions of Rad9 for Preserving Genomic Integrity
Current Genomics The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.
Current Medicinal Chemistry Tumor-Targeting Peptides and Small Molecules as Anti-Cancer Agents to Overcome Drug Resistance
Current Medicinal Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis
Current Pharmaceutical Design Statin-Induced Myotoxicity: Pharmacokinetic Differences among Statins and the Risk of Rhabdomyolysis, with Particular Reference to Pitavastatin
Current Vascular Pharmacology Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets